List of Clinical Studies


Oncology

Study Name	Principal Investigator

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756). Hypothesis is that pembrolizumab in combination with the protocol-specified neoadjuvant anticancer therapy with respect to either pathological complete response or event-free survival. Read more.	Yadyra Rivera, MD

A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist). The hypothesis is that a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease. Read more.	Elan Diamond, MD

Oncology - Breast Cancer

Study Name	Principal Investigator

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756). Hypothesis is that pembrolizumab in combination with the protocol-specified neoadjuvant anticancer therapy with respect to either pathological complete response or event-free survival. Read more.	Yadyra Rivera, MD

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer. Read more.	Yadyra Rivera, MD

Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (veliparib) in metastatic triple-negative Breast Cancer and/or BRCA mutation-associated Breast Cancer . Read more.	Yadyra Rivera, MD

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer. Read more.	Yadyra Rivera, MD

Oncology - Prostate Cancer

Study Name	Principal Investigator

A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist). The hypothesis is that a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease. Read more.	Elan Diamond, MD

We are open.
We are clean.
We are ready.

Medical Care

Cancer Care

Specialty Services

Medical Care & Treatments

Patients & Visitors

For Patients

For Visitors

Directions & Parking

Amenities & Services

Community Health

About Holy Name Medical Center

Quick Links

Key Phone Numbers

Medical Center Operator

Physician Referral Service

Patient Information

Foundation (Donations)

Human Resources

Medical Staff Office

In This Section

For More Information:

List of Clinical Studies

We are open.We are clean.We are ready.

Medical Care

Cancer Care

Specialty Services

Medical Care & Treatments

Patients & Visitors

For Patients

For Visitors

Directions & Parking

Amenities & Services

Community Health

About Holy Name Medical Center

Quick Links

Key Phone Numbers

Medical Center Operator

Physician Referral Service

Patient Information

Foundation (Donations)

Human Resources

Medical Staff Office

List of Clinical Studies

In This Section

For More Information:

List of Clinical Studies

We are open.
We are clean.
We are ready.